Keyword: Tecfidera

Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.

Biogen boosted the stickers on some of its key MS medications Monday, and the payoff could make up for sales lost to new rivals.

In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.

Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.

The $125,000-per-injection price of its new rare disease drug Spinraza has now kept it from getting coverage and turning in $203 million in sales for its second quarter on the market.

Biogen and AbbVie’s MS drug Zinbryta faces new restrictions in Europe at a time when tough payers and new challengers are roiling the field.

A U.S. appeals court sided with Biogen in a lawsuit claiming execs weren't open with investors about Tecfidera's sales trajectory after the death of a patient taking the drug.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth noting.

Facing stepped-up competition for its critical MS franchise, Biogen CEO Michel Vounatsos says his company's ready to try some "innovative" payer deals.